Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Blood|September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphomaJia Ruan, Peter Martin, Paul Christos, et al.
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyToby A Eyre, Anna Schuh, William G Wierda, et al.
Blood|January 29, 2021
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse modelsTiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, et al.
Cell Genomics|October 11, 2025
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-MultiMinwoo Pak, Mirca S Saurty-Seerunghen, Kellie Wise, et al.
Blood Advances|January 4, 2018
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironmentSara Serra, Tiziana Vaisitti, Valentina Audrito, et al.
Blood|March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Pageof 14